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Abstract
Background:  Kaposi's sarcoma (KS) is a mesenchymal tumour associated with human
herpesvirus-8 infection. However, the incidence of human herpesvirus-8 infection is far higher than
the prevalence of KS, suggesting that viral infection per se is not sufficient for the development of
malignancy and that one or more additional cofactors are required.
Discussion: Epidemiological data suggest that iron may be one of the cofactors involved in the
pathogenesis of KS. Iron is a well-known carcinogen and may favour KS growth through several
pathways. Based on the apoptotic and antiproliferative effect of iron chelation on KS cells, it is
suggested that iron withdrawal strategies could be developed for the management of KS. Studies
using potent iron chelators in suitable KS animal models are critical to evaluate whether iron
deprivation may be a useful anti-KS strategy.
Summary: It is suggested that iron may be one of non-viral co-factors involved of KS pathogenesis
and that iron withdrawal strategies might interfere with tumour growth in patients with KS.
Background
Kaposi's sarcoma (KS) is a mesenchymal tumour that has
been identified in different clinical/epidemiological set-
tings: classic KS, an indolent form usually found in elderly
men of Mediterranean or Eastern European origin; Afri-
can-endemic KS, which usually involves the lower extrem-
ities (figure 1) and which existed well before the HIV
epidemic in some equatorial countries of Africa; immuno-
suppressive drug-related KS; AIDS-associated KS and HIV-
negative gay-related KS. All these forms of KS share a sim-
ilar histopathology characterised by the proliferation of
spindle-shaped cells, by neoangiogenesis, by erythrocyte
extravasation and by the presence of haemosiderin-laden
macrophages and other inflammatory cells.
A large body of evidence indicates that human herpesvi-
rus-8 (HHV-8) has an important etiologic role in the
pathogenesis of KS; 1) HHV-8 can be detected in all the
epidemiological and histological forms of KS [1-3] and
can directly infect the KS spindle cells [4,5]; 2) HHV-8
encodes several genes that can independently transform
cells to a malignant phenotype [6]; 3) infection precedes
development of the tumour and tracks tightly with KS risk
[3]. However, HHV-8 infection appears as a very low risk
factor for KS development. Most reports suggest a 2 to
10% global seroprevalence of HHV-8, with much higher
rates in some areas [7,8]. Assuming a 5% prevalence of
HHV-8 in the United States and a 1970s baseline inci-
dence of KS in men in the United States of about 0.3 cases
per 100000 men, the HHV-8 rate would be one case of KS
in every 17000 HHV-8 infections [9]. In addition, sero-
prevalence rates in different geographic areas do not
always correlate with KS development. Eighty-nine per-
cent to 100% of serum samples from the general popula-
tion in non-KS-endemic African areas such as Gambia or
the Ivory Coast, proved to be positive; such a rate is higher
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Aggressive African-endemic KS of the foot Figure 1
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than the 40% rate found in sub-Saharan Africa, where KS
is endemic [10]. A similar finding among Brazilian-Amer-
indians has been published; seroprevalence was 53%,
although KS has never been reported in this population
[11]. Another puzzling finding is the similarity of rates of
HHV-8 infection among men and women in Africa [10].
Since the KS found in Africa is about 8 to 10 times as com-
mon among men as among women, there must be some
reason other than HHV-8 infection to explain this
difference.
Thus, there is now compelling evidence that HHV-8 is a
necessary, albeit not sufficient, cause of KS and that one or
more additional cofactors are required. These co-factors
may represent a target for the prevention and/or treatment
of KS.
Discussion
High incidence of KS in iron oxide-rich volcanic clays
Endemic KS in Africa predated the HIV epidemic and
showed evidence of geographic restriction [12,13], sug-
gesting a genetic or an environmental cofactor. The high-
est prevalence of endemic KS in Africa lies in a broad strip
running from the Uganda, Sudan, and Democratic Repub-
lic of Congo border southwards through Rwanda and
Burundi. In the Northeastern provinces of the Democratic
Republic of Congo, and in Rwanda and Burundi, KS
accounts for up to 17% of adult male malignancies
[13,14]. Prevalence diminishes rapidly away from this
endemic region. Amazingly, these areas of high preva-
lence of endemic KS are characterised by a common geo-
logic substratum, composed of iron oxide-rich volcanic
clays (figure 2). This observation led Dr. Ziegler to suggest
that chronic exposure to volcanic clays plays a role in the
pathogenesis of African-endemic KS [14]. His intriguing
hypothesis was that ultrafine particles of clay penetrate
the skin of the feet during barefoot walking, leading to
dermal lymphatic damage and to impaired local immu-
nity. Further data have strengthened the hypothesis of soil
exposure and percutaneous penetration of ferromagnetic
particles as a risk factor for KS. More particularly, barefoot
walking, time spent in contact with water and exposure to
wet soils appear as important risk factors for KS in Uganda
[15,16]. In water, a clay emulsion disaggregates into parti-
cles less than 2 µm, a size that can readily enter sweat
glands of the feet [17]. While cultivating (especially in the
rainy season when clay soils are pliant and workable), soil
particles might thus enter the sweat glands and pores of
the feet, perhaps aided by micro-abrasions caused by the
high quartzite content of these soils. In this perspective,
we have reported the case of a metallurgist with classic KS
involving his palm. Iron filings were detected in the
underlying cutaneous tissues by magnetic resonance
imaging, supporting the hypothesis that percutaneous
penetration of iron may favour the development of KS
[18].
Exposure to volcanic clays may also help to explain the
distribution of classic KS in the Mediterranean, prevalent
in volcanic regions such as the Pelopenese, Sardinia and
Sicily. Supporting this hypothesis, Montella et al. noted
that the risk of classic KS was twofold higher among peo-
ple born near Mount Vesuvius than among people born in
neighbouring areas [19]. Interestingly, a magmatic sub-
strate similar to that of the East African Rift system (extru-
sive igneous rocks composed of mafic (and hence iron
oxide-rich) minerals) [20] is also present in Iceland and in
the Faroe Islands which are other geographic areas known
to exhibit surprisingly high incidence rates of classic KS
[21]. One of the characteristics of these mafic minerals is
that they are highly weatherable, allowing a significant
release of iron compounds in the environment, such as in
water or in vegetables [22]. The unusually high prevalence
of the classic and endemic forms of KS in regions of inter-
continental rifts and volcanism may thus point to pro-
longed exposure to indigenous iron oxide-rich volcanic
soils as a common aetiological risk factor.
Carcinogenic role of iron
Several observations have been made linking cellular iron
content to the development of cancers [23]. In prospective
studies in animals, administration of excessive amounts
of injected or oral iron increases markedly the risk of ade-
nocarcinomas, colorectal tumours, hepatomas, mammary
tumours, mesotheliomas, renal tubular cell carcinomas,
and sarcomas [23]. In humans, injections of iron com-
plexes have been observed to result in sarcomas at the sites
of deposition [24]. Similarly, inhalation of industrial
sources of iron may be responsible for respiratory tract
neoplasias [25,26]. Patients with hemochromatosis, a
genetic disease characterised by increased iron absorp-
tion, show a markedly enhanced susceptibility to primary
liver cancer and various other malignancies [27]. Patients
with moderate elevation of body iron levels may also have
an increased risk of neoplasms of various kinds [28,29].
The pathogenic role of iron in cancer development and/or
progression is not fully understood. Several carcinogenic
pathways have schematically been described: (a) iron is
an essential element for dividing cells, because it is incor-
porated in numerous enzymes that play a role in DNA
replication and cellular metabolism. More particularly,
iron can directly promote the growth of some cancer cells
[30], probably through its role in the activation of ribonu-
cleotide reductase, a key-enzyme in DNA synthesis,
responsible for the reduction of ribonucleotides to deox-
yribonucleotides [31]; (b) iron may promote the forma-
tion of mutagenic hydroxyl radicals [23]; (c) iron excess
diminishes host defences through inhibition of theBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/1
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activity of CD4 lymphocytes and through the suppression
of the tumoricidal action of macrophages [23]; (d) iron
can enhance host cell production of viral nucleic acids
[32] which may be involved in the development of some
human cancers. Other data support more specifically a
direct role of iron in the pathogenesis of KS: 1) the addi-
tion of iron salts to KS-derived cells can stimulate their
growth [33]; 2) iron can induce the expression of anti-
apoptotic signals in human dermal microvascular
endothelial cells [34], which may alter the homeostasis of
microvessels and promote neo-angiogenesis. Interest-
ingly, one of the histological hallmark of KS is the pres-
ence of ferritin granules and the presence of
haemosiderin-laden macrophages (figure 3). Even at the
early 'patch-stage' of KS development, red blood cell
extravasation and the presence of siderophages are
encountered, providing a possible continuous source of
iron for endothelial and KS cells.
Iron status in individuals prone to develop KS
Amazingly, a high iron load is expected to be found in the
different epidemiological forms of KS. Iron load is ele-
vated in renal transplant recipients who had received
blood transfusions for years before the availability of
erythropoietin and before transplantation. Iron load
could also be higher in patients with episodes of haemo-
lytic anaemia which are common features in Central
Africa or in Mediterranean areas, mostly secondary to glu-
cose-6-phosphatase deficiency, thalassemia or sickle cell
anaemia. In HIV infection, the alteration of iron metabo-
lism has been recognised in a variety of ways [32]. The
majority of patients in advanced stages of AIDS are hypo-
ferrimic and moderately hyperferritinemic, and they have
increased deposition of iron-ferritin and/or haemosiderin
in cells of the bone marrow, brain white matter, skeletal
muscle, and sometimes in the liver. The 'iron hypothesis'
may also provide a non-hormonal explanation for the
lower prevalence of KS among women, as they are known
to have lower iron reserves than men. In this connection,
it may also help to understand the reported disappearance
of KS lesions during or just after pregnancy [35]. It is inter-
esting to note that there are high incidence rates of KS
among Bantu in the South African Transvaal [36] and that
these individuals are known to frequently suffer from iron
Landscape in the Kigali area (Rwanda): the red-brown colour of the soil is related to an intense weathering of the minerals of  the geological substratum with massive release of fine particles of iron oxides and iron hydroxides Figure 2
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overload resulting from the interaction between their gen-
otype and an environmental factor – namely, increased
amounts of bioavailable iron in the diet. The source of
this dietary iron is a traditional fermented beer that is
home-brewed from local crops in steel drums [37].
Iron withdrawal strategies: a role for the management of 
KS?
Based on a possible role of iron in tumour development,
several studies have shown that iron withdrawal strategies
possess considerable activity in vitro in inhibiting tumour
growth [38,39]. More particularly, we found that the
chemically unrelated iron chelators desferrioxamine
(DFO) and deferiprone could inhibit the growth and
induce the apoptosis of human KS-derived cells at clini-
cally achievable concentrations [40], suggesting that iron
chelation may represent an experimental therapeutic
approach for the treatment of KS. Iron chelators have also
been shown to inhibit vascular cell adhesion molecule-1
(VCAM-1) expression in human dermal microvascular
cells [41]. As VCAM-1 may favour angiogenesis and
account for inflammation-augmented tumour develop-
ment [42,43] and as it is used by cancer cells to enhance
metastatic implantation and spread [42], VCAM-1 inhibi-
tion represents another mechanism through which iron
chelation might prevent KS growth.
We previously initiated studies investigating the effect of
DFO on the growth of immortalized KS-Y1 cells in immu-
nodeficient mice, which resulted in paradoxical enhance-
ment of the growth of the xenografts [44]. These results
could be related to the upregulation of angiogenic growth
factors by DFO [45] as well as to its short half-life in
mouse plasma [46] and to its subsequent inability to
induce significant iron depletion in non-iron-overloaded
mice [44]. Another disadvantage of DFO is its poor ability
to permeate cell membranes and bind intracellular Fe
pools [47]. Obviously, investigation of iron chelators
showing higher iron chelation and use of animal models
closely mimicking human KS are required.
'Plaque-stage' KS showing the presence of numerous haemosiderin-laden macrophages Figure 3
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Several chelators with greater antiproliferative and/or bet-
ter pharmacokinetics than DFO have been recently devel-
oped [47]. Among the most promising molecules are the
2-pyridoxal isonicotinyl hydrazone (PIH) analogues [39].
Their antiproliferative activity is much greater than that of
DFO and is comparable to that of bleomycin and cisplatin
[48]. These molecules affect the expression of several mol-
ecules involved in cell cycle through their ability to chelate
intracellular iron [39]. As PIH analogues may have poten-
tial as agents to treat cancer, they represent potential drugs
for KS therapy. Another promising chelator with greater
efficacy than DFO is ICL670A [49], which is an orally
active representative of a new class of tridentate iron che-
lator developed for the treatment iron overload and which
has been shown to be relatively well-tolerated in phase III
studies [50]. Triapine, a ribonucelotide reductase inhibi-
tor, has completed phase I studies in patients with
advanced leukaemia and with advanced solid tumours
[51,52] and is currently in phase II clinical trial as an anti-
cancer agent. CP502, GT56-252, NaHBED, and MPB0201
are examples of other new chelators in preclinical/clinical
development [53].
Models closely mimicking human KS are obviously
required to evaluate the effect of potential anti-KS drugs.
Although there is currently no animal model that accu-
rately represents KS pathogenesis, a number of mouse
models have been established that attempt to address spe-
cific factors known to contribute to the development of
the disease. In early studies, transformed KS cell lines such
as KS Y-1 were injected into nude mice, which led to the
development of KS-like lesions. This model was used to
investigate the effect of various therapies on KS growth,
such as human chorionic gonadotropin or interleukin-4
[35,54]. However, these xenografts models may be
flawed, because none of the KS cells used for tumour
establishment harbour HHV-8 sequences, as opposed to
human KS lesions. More promising models have recently
been obtained by creating transgenic mice expressing the
HHV8-encoded chemokine receptor (viral G protein-cou-
pled receptor) within hematopoietic cells [55]. The mice
develop angioproliferative lesions in multiple organs that
morphologically resemble KS lesions. These lesions are
characterized by a spectrum of changes ranging from ery-
thematous maculae to vascular tumours, by the presence
of spindle and inflammatory cells, and by expression of
vGPCR, CD34, and vascular endothelial growth factor
[55]. In another model, HHV-8 was injected into normal
human skin transplanted onto SCID mice. Injection of
HHV-8 induced lesion formation that is morphologically
and phenotypically consistent with KS, including the pres-
ence of angiogenesis and spindle-shaped cells latently
infected with HHV-8 [56]. This in vivo system has the
advantage of using human skin cells as the target of the
virus, and may be the most accurate model of KS; how-
ever, it does not completely mimic KS and is difficult to
reproduce [57].
Summary
At present, several types of iron withdrawal strategies have
been shown to possess considerable activity in vitro in
inhibiting tumour growth. Based on the probable role of
iron in KS pathogenesis, it is suggested that manipulations
of iron load might interfere with tumour growth in
patients with KS. However, further studies using potent
iron chelators in suitable KS animal models are critical to
evaluate whether iron deprivation may be a useful anti-KS
strategy.
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